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Abstract
Bioactive lipids, including oxylipins, endocannabinoids, and related compounds may func-
tion as specific biochemical markers of certain aspects of inflammation. However, the post-
prandial responsiveness of these compounds is largely unknown; therefore, changes in the
circulating oxylipin and endocannabinoid metabolome in response to a challenge meal
were investigated at six occasions in a subject who freely modified her usual diet. The die-
tary change, and especially the challenge meal itself, represented a modification of precur-
sor fatty acid status, with expectedly subtle effects on bioactive lipid levels. To detect even
the slightest alteration, highly sensitive ultra-performance liquid chromatography (UPLC)
coupled to electrospray ionization (ESI) tandem mass spectrometry (MS/MS) methods for
bioactive lipid profiling was employed. A previously validated UPLC-ESI-MS/MS method for
profiling the endocannabinoid metabolome was used, while validation of an UPLC-ESI-MS/
MS method for oxylipin analysis was performed with acceptable outcomes for a majority of
the parameters according to the US Food and Drug Administration guidelines for linearity
(0.9938 < R2 < 0.9996), limit of detection (0.0005–2.1 pg on column), limit of quantification
(0.0005–4.2 pg on column), inter- and intraday accuracy (85–115%) and precision (< 5%),
recovery (40–109%) and stability (40–105%). Forty-seven of fifty-two bioactive lipids were
detected in plasma samples at fasting and in the postprandial state (0.5, 1, and 3 hours after
the meal). Multivariate analysis showed a significant shift of bioactive lipid profiles in the
postprandial state due to inclusion of dairy products in the diet, which was in line with univar-
iate analysis revealing seven compounds (NAGly, 9-HODE, 13-oxo-ODE, 9(10)-EpOME,
12(13)-EpOME, 20-HETE, and 11,12-DHET) that were significantly different between back-
ground diets in the postprandial state (but not at fasting). The only change in baseline levels
at fasting was displayed by TXB2. Furthermore, postprandial responsiveness was detected
for seven compounds (POEA, SEA, 9(10)-DiHOME, 12(13)-DiHOME, 13-oxo-ODE, 9-
HODE, and 13-HODE). Hence, the data confirm that the UPLC-ESI-MS/MS method perfor-
mance was sufficient to detect i) a shift, in the current case most notably in the postprandial
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bioactive lipid metabolome, caused by changes in diet and ii) responsiveness to a challenge
meal for a subset of the oxylipin and endocannabinoid metabolome. To summarize, we
have shown proof-of-concept of our UPLC-ESI-MS/MS bioactive lipid protocols for the pur-
pose of monitoring subtle shifts, and thereby useful to address lipid-mediated postprandial
inflammation.
Introduction
The postprandial state, which is the state immediately following a meal, displays a dynamic
course of events in response to the food ingested. It is an important period during which tran-
sient inflammation can occur. The current hypothesis is that during the normal homeostatic
postprandial response, inflammatory compounds are transiently produced, which cause no
harmful effects. In the case of a maladaptive postprandial response, during the so-called “post-
prandial metabolic inflammation”, an exaggerated and protracted inflammation may occur,
linked to an unfavorable immune response [1]. This postprandial modification of innate
immunity has been suggested to be responsible for the adverse effects of certain dietary fatty
acids on, for instance, cardiovascular health. In general, the ω6 polyunsaturated fatty acids
(PUFA) promote postprandial inflammation, while the ω3 PUFA suppress it. But the effects of
fatty acid meal composition on inflammatory events and cardiovascular health are conflicting
and have mainly been studied in models of chronic exposures, whereas the significance of post-
prandial adaptation remains unclear [2–7]. This gap in knowledge highlights the need for reli-
able biochemical markers of lipid-mediated postprandial inflammation. Several candidates
have been investigated, including cytokines and bioactive lipids [8–11]. The bioactive lipid
family of oxylipins is a particularly compelling group of molecules for postprandial studies due
to its role in endothelial inflammation and cardiovascular disease [12, 13].
The term oxylipin includes ω6 derived 20-carbon eicosanoids (e.g. prostaglandins and leu-
kotrienes), as well as other oxidized fatty acid metabolites ranging from well-established
inflammatory mediators to potential key molecules of inflammation [14]. Oxylipins have long
been recognized for their involvement in inflammation through the catabolic pathways of
cyclooxygenase (COX), lipooxygenase (LOX), and cytochrome P450 (CYP). Furthermore,
accumulating evidences suggest that another family of bioactive lipids, the endocannabinoids,
share the same catabolic pathways and may be responsible for at least some of the beneficial
anti-inflammatory effects from drugs inhibiting these enzymes [15]. Endocannabinoids are
also fatty acid metabolites with signaling properties, but unlike oxylipins, they are able to bind
to and activate cannabinoid receptors [16]. Most studied are anandamide (AEA) and 2-arachi-
donyl glycerol (2-AG), which are associated, among other things, with the regulation of inflam-
mation and appetite [15, 17–19]. Other N-acylethanolamines (NAEs), monoacylglycerols
(MAGs) and related compounds are characterized as “cannabimimetic” when they are able to
activate cannabinoid receptors, or “entourage compounds” which are unable to activate CB
receptors, but still modify the activity of true endocannabinoids by inhibiting their degradation
and metabolism [20–23].
Even though oxylipins and endocannabinoids are connected, they are rarely investigated
together. One reason for this lack of experiments is the challenging analytical protocol. Never-
theless, simultaneous analysis of oxylipins and endocannabinoids has occasionally been per-
formed, revealing valuable information such as changes associated with dietary fish oil in mice
[24–27]. Furthermore, separate investigations of oxylipins and endocannabinoids have
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underscored the importance of studies on the effect of dietary fatty acids on circulating bioac-
tive lipid levels [28–30]. However, the postprandial responsiveness per se of oxylipins and
endocannabinoids is still poorly understood, which is necessary to elucidate if these com-
pounds are to be used as markers for studies on postprandial inflammation. The challenge
meal study design offers a suitable approach to test if a method is able to detect subtle shifts in
the metabolome, as illustrated by anandamide and other NAE shifts in the postprandial state
[31, 32]. Furthermore, the feasibility of a challenge meal has previously been demonstrated by
the reproducibility of individual metabolic responsiveness of circulating fatty acids [33]. There-
fore, the challenge meal study design was used to test the performance of ultra-performance
liquid chromatography (UPLC) coupled with electrospray ionization (ESI) tandem mass spec-
trometry (MS/MS) methods for the analysis of a selected panel of oxylipins, endocannabinoids,
cannabimimetic and entourage compounds. Thereby, we did not relate the levels to free fatty
acids (like in [31]), but we extended the investigation of the postprandial state compared to
[32], and added compounds beyond what has been reported previously [31–33].
The endocannabinoid metabolome was analyzed using a previously validated UPLC-E-
SI-MS/MS method [34], while a novel UPLC-ESI-MS/MS method for analysis of the oxylipin
metabolome was developed and validated for application to human plasma at fasting and in
the postprandial state after a well-defined meal. The measurements were repeated for the same
individual on two different diets, vegan and vegetarian, to investigate the effects of modifica-
tions of precursor fatty acid status introduced both by the background diet, and the challenge
meal itself, on the circulating bioactive lipid levels. Such subtle shifts in phenotype and respon-
siveness are difficult to detect with markers that were developed to detect instead the major
changes that occur in disease vs. health. For example, C reactive protein (CRP), the most well-
known marker of systemic inflammation, differentiates between individuals with overt disease
compared with healthy controls [35, 36], and changes in response to major shifts in diet [37,
38]. However, CRP does not always change in response to more subtle shifts in diet or weight
loss [39, 40], and does not change in the postprandial state [41–44]. It is increasingly recog-
nized that quantification of a standardized perturbation of metabolic homeostasis induced by
dietary interventions is more informative than quantification of only the homeostatic situation
(at fasting) [45]. Thus, more sensitive and specific markers of inflammation that can detect
more subtle differences between different phenotypes and shifts in response to meals and
changes in diet are needed.
To that end, the aim of this study was to develop comprehensive methods to analyze the cir-
culating oxylipin and endocannabinoid metabolome (totaling fifty-two metabolites) with suffi-
cient sensitivity to detect and quantify subtle differences introduced by changes in background
diet before and after a challenge meal at multiple test occasions. We applied our validated
method for endocanabinoids and related compounds [34], and validated a new method for
oxylipins Despite the fact that several methods dealing with quantification of oxylipins previ-
ously have been reported [24, 33, 46–49], method validation when using new equipment is nec-
essary to ensure data quality and reproducibility [24]. Furthermore, there is a great need to
employ methods with improved sensitivity and specificity due to the extreme low levels that
most of the bioactive lipids are found at in healthy individuals.
By studying the postprandial variability of thirty-five circulating oxylipins, and twelve
endocannabinoids and similar compounds, we were able to show proof-of-concept of our
methods for the purpose of monitoring lipid-mediated postprandial inflammation. Our results
highlighted that a well-defined challenge meal may reduce noise in the postprandial bioactive
lipid metabolome compared to the fasting state, and thereby more differences in relation to
subtle effects (here represented by changes in background diet) may be detected in the post-
prandial state than at fasting.
Oxylipins and Endocannabinoid Levels in Postprandial Inflammation
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Materials and Methods
Study design
This was a pilot study using the challenge meal study design of a single female subject continu-
ously eating the diet of her choice, who freely changed diet from vegan to vegetarian. From this
point the vegan diet will be denominated as “usual diet” and vegetarian diet as “modified diet”
since we are not making any attempt to relate the actual changes in diet to biological markers,
neither on individual level nor on population level. The subject was not fed anything or told to
eat anything specific as part of this study but instead was a free-living individual. She was a
healthy female with no disease diagnoses, except for celiac disease, with a body mass index of
20, 29 years of age when the study began, and 30 when it ended. Body weight was monitored
throughout the study and fluctuated between 55.5 to 57 kg. She was tested three times on each
background diet using a challenge meal of bananas (in agreement with her dietary choice
according to her diet records). The study protocol was defined according to the human
research ethics in the Declaration of Helsinki and did not require anything beyond that the
subject was able to donate blood safely since she was recruited under a methods development
study protocol, which was approved by the Institutional Review Board of the University of Cal-
ifornia, Davis. Written informed consent was obtained prior to study commencement.
After being on her usual diet for 5 years, refraining from meat and dairy products, the sub-
ject modified her diet by inclusion of dairy products. Other consumed food products, including
abstaining from eating all gluten containing foods, remained similar as (assessed by compari-
son of seven-day dietary records from both dietary phases). The first set of meal challenges was
performed during a period of eight days before inclusion of dairy products to the background
diet. The amount of dairy products was then gradually increased during one year to a steady
state, which was kept for 33 weeks until the second set of meal challenges was performed.
Dietary intake was assessed with seven-day dietary records. Nutrient information for each
day was analyzed from the dietary records using the NutriHand program (Nutrihand Inc., Sor-
aya, CA) from reference nutrient data for individual foods using the USDA National Nutrient
Database for Standard Reference. Nutrient data were averaged together for all 7 days within
each dietary period and then compared by two-tailed t-tests. The main weekly differences
between the diets during the 33 weeks were on average: 2 L yoghurt, 1.7 eggs, 200 g cheese and
2.1 dL cream and butter per week in the modified diet. This change did not affect the overall
consumption of calories, proteins, total fats or carbohydrates, but resulted in a shift in the rela-
tive composition of fatty acids (S1 Table). More specifically, during the modified diet the sub-
ject consumed lower amounts of fiber, magnesium, copper, vitamin C, total PUFAs and
18:2n6, and higher amounts of calcium, vitamin B12, total saturated fatty acids (as well as indi-
vidual short and medium chain fatty acids), the monounsaturated fatty acid 16:1 and
cholesterol.
The subject was tested three times on each background diet on three non-consecutive days
during a time frame of up to two weeks totaling six test occasions. No major lifestyle changes
occurred during the course of the study, as monitored with physical activity and health ques-
tionnaires. On each test day, the subject came to the study center after an overnight fast, and
was weighed and underwent a questionnaire to exclude recent changes in diet, lifestyle, physi-
cal activity, medication or supplement use. The challenge meal was then consumed within
5–7 min and consisted of 335.6 g–348.5 g of banana providing approximately 15% of daily
calories. A fasting blood sample was collected and postprandial blood draws were performed
at 0.5, 1, and 3 hours after the finished meal (Fig 1) using lavender-top EDTA tubes. Whole
blood was centrifuged in a tabletop ultracentrifuge for 10 minutes at room temperature at
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3000 rpm within one hour of collection. Plasma (containing both unesterified and esterified
fatty acids) was then collected and aliquoted and stored at –80°C until analysis.
Chemicals and reagents
Despite the excessive number of potential oxylipins, only 50 are usually reported in human
plasma [27, 47]. Gathering that information and based on the purpose of our research topic,
we selected 37 oxylipins for inclusion in our method to profile the oxylipin metabolome. Fur-
thermore, 15 NAEs, MAGs and related compounds were analyzed in order to profile the endo-
cannabinoid metabolome. Chemical structures of all analytes are shown in S1 Fig.
The following native, internal, and recovery standards were purchased from Cayman
Chemicals (Ann Arbor, MI, USA): AEA, 2-AG, O-AEA, 2-AGe, NADA, PEA, OEA, DEA,
NAGly, EPEA, DHEA, POEA, LEA, SEA, 2-LG, AEA-d8, 2-AG-d8, OEA-d4, and DHEA-d4
(for analysis of NAEs, MAGs and related compounds); and PGF2α, PGE2, TXB2, PGD2, 5(6)-
EET, 8(9)-EET, 11(12)-EET, 14(15)-EET, 5,6-DHET, 8,9-DHET, 11,12-DHET, 14,15-DHET,
9(10)-EpOME, 12(13)-EpOME, 9(10)-DiHOME, 12(13)-DiHOME, 5-HETE, 8-HETE,
9-HETE, 11-HETE, 12-HETE, 15-HETE, 20-HETE, 9-HODE, 13-HODE, 15(S)-HETrE,
12-HEPE, 17-HDoHE, 5-oxo-ETE, 12-oxo-ETE, 15-oxo-ETE, 13-oxo-ODE, LTB4, Resolvin
D2, Resolvin D1, 12-[[(cyclohexylamino)carbonyl]amino]-dodecanoic acid (CUDA), 12(13)-
DiHOME-d4, 12(13)-EpOME-d4, 9-HODE-d4, PGE2-d4, and TXB2-d4 (for oxylipin analysis).
The oxylipins 9,10,13-TriHOME and 9,12,13-TriHOME were obtained from Larodan (Swe-
den, Malmö). Acetonitrile (ACN) and methanol (MeOH) were fromMerck (Darmstadt, Ger-
many). Isopropanol was from VWR PROLABO (Fontenay-sous-Bois, France). Ammonium
acetate (CH3COONH4) was purchased from Scharlau Chemie (Barcelona, Spain). Acetic acid
was purchased from Aldrich Chemical Company, Inc. (Milwaukee, WI, USA). Butylhydroxy-
toluene (BHT) was from Cayman Chemical (Ann Arbor, MI, USA) and ethylenediaminetetra-
acetic acid (EDTA) from Fluka Analytical, Sigma-Aldrich (Buchs, Switzerland). Glycerol was
from Fischer Scientific (Loughborough, UK). All solvents and chemicals were of HPLC grade
or higher. Water was purified by a Milli-Q Gradient system (Millipore, Milford, MA, USA).
Internal standards (IS). Deuterated compounds were used as internal standards (IS) for
quantification purposes and were added to samples before extraction to mimic the extraction
of the endogenous compounds. Three IS were used for endocannabinoid quantification (AEA-
Fig 1. The study design. After an overnight fast, blood was collected and thereafter the challenge meal was consumed. Postprandial blood collection was
done at 0.5, 1, and 3 h after finished meal. The meal challenge was repeated at six occasions in total. Hour of blood collection varied between experiments,
illustrated by time spans.
doi:10.1371/journal.pone.0132042.g001
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d4, OEA-d4 and 2-AG-d8), and five for oxylipin quantification (12(13)-DiHOME-d4, 12(13)-
EpOME-d4, 9-HODE-d4, PGE2-d4, and TXB2-d4). For each native compound, a suitable IS was
selected based on structural similarities (S2 Table). Recovery rates of each IS were calculated
by adding the recovery standard DHEA-d4 (endocannabinoids) or CUDA (oxylipins) in the
last step before analysis [46].
Standard stock solutions. Analytical quantification standards were used as ready-made
standard stock solutions or as solutions prepared from solid substances and stored at -80 °C.
2-AG, O-AEA, 2-AGe, 2-LG and 5(6)-EET were prepared and stored in ACN and the other
standards were prepared and stored in ethanol to yield a final stock solution concentration of
250 μg/mL (endocannabinoids) and 100 or 1000 μg/mL (oxylipins). Stock solutions of IS were
prepared to reach a final concentration of 40 μg/mL (endocannabinoids) and 10 μg/mL
(oxylipins).
Standard curve preparation. Further dilutions of each stock solution were made with
methanol at ten different calibration levels for quantification purposes, prepared fresh on a
weekly basis for endocannabinoids and stored at -80°C for oxylipins (S3 and S4 Tables). The
lowest concentration in each calibration curve was further diluted to determine limit of quanti-
fication (LOQ) and detection (LOD) at a signal to noise ratio (S/N) of 10 and 3, respectively.
Endocannabinoid quantification
Analysis of NAEs, MAGs and related compounds was done according to our previously vali-
dated method [34]. Briefly, the plasma samples (300–500 μL) were subjected to solid phase
extraction (SPE) using Waters Oasis HLB cartridges (60 mg of sorbent, 30 μm particle size). A
MiniVac system (Farmingdale, NY, USA) was used to evaporate the eluates from the SPE car-
tridges. The analytes were then reconstituted in 100 μL MeOH and 10 μL recovery standard
was added before UPLC-ESI-MS/MS analysis. The UPLC system consisted of a Waters Acquity
Ultra Performance equipment (Milford, MA, USA) with a binary pump, a thermostated col-
umn compartment and an autosampler. LC separation was achieved using a Waters BEH C18
column (2.1 mm x 150 mm, 1.7 μm particle size) at 60°C, with an injection volume of 10 μL.
MilliQ water (A) and 10 mM CH3COONH4 in MeOH (B) were used as mobile phase following
this gradient elution: 0.0–9.0 min 79% B, 9.0–9.5 min 79–90% B, 9.5–10.5 min 90% B, 10.5–
14.0 min 79% B, at a flow rate of 0.4 mL/min. The autosampler temperature was maintained at
10°C. The mass analysis was done on a Waters triple quadrupole MS (Micromass Quattro
Ultima) equipped with an electrospray ionization source operating in positive mode (ESI+). N2
was used as drying gas (60 L/hr) and Ar as nebulization gas (650 L/hr). Source and desolvation
temperatures were 150°C and 350°C, respectively.
Oxylipin quantification
A previously published SPE protocol was adapted for extraction of oxylipins from plasma [46].
On the day of extraction, the plasma samples were thawed at room temperature and centri-
fuged. SPEWaters Oasis HLB cartridges (60 mg sorbent, 30 μm particle size) were first washed
with 2 mL of ethyl acetate, 4 mL of methanol, and 4 mL of 95:5 v/v water/MeOH with 0.1% ace-
tic acid (WS). A quantitative volume of plasma (300–500 μL depending on the amount sup-
plied) was loaded onto the SPE cartridges and spiked with 10 μL of internal standard solution
(50 ng/mL for 12(13)-DiHOME-d4 and 12(13)-EPOME-d4, and 25 ng/mL for 9(S)-HODE-d4,
PGE2-d4 and TXB2-d4) and 10 μL antioxidant solution (0.2 mg/mL BHT/EDTA in methanol/
water (1:1)). The SPE cartridges were then washed with 4 mL of WS, dried under high vacuum
for about 1 minute, and eluted with 2 mL methanol and 2 mL ethyl acetate into polypropylene
tubes containing 6 μL of a glycerol solution (30% in methanol). Glycerol operates as a trap
Oxylipins and Endocannabinoid Levels in Postprandial Inflammation
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solution for the analytes. Eluates were evaporated under vacuum (MiniVac system, Farming-
dale, NY, USA) and residues were then reconstituted in 100 μL methanol and tubes were vor-
texed. The solutions were transferred to LC vials and 10 μL of the recovery standard solution
was added (5 ng/mL CUDA) and UPLC-AJST-ESI-MS/MS analysis was performed immedi-
ately in randomized order. The Agilent UPLC system (Infinity 1290) was coupled to an Agilent
6490 Triple Quadrupole system equipped with the iFunnel Technology source (Agilent Tech-
nologies, Santa Clara, CA, USA). The UPLC column used was the same as described for the
endocannabinoid methodology, a Waters BEH C18 column (2.1 mm x 150 mm, 2.5 μm particle
size), and 10 μL injection volume was employed. Different mobile phase composition and dif-
ferent gradients were compared in order to achieve optimal separation for all compounds,
especially between critical isomer pairs. The optimal conditions were found with 0.1% acetic
acid in MilliQ water (A) and acetonitrile:isopropanol (90:10) (B) using the following gradient:
0.0–3.5 min 10–35% B, 3.5–5.5 min 40% B, 5.5–7.0 min 42%B, 7.0–9.0 min 50% B, 9.0–15.0 min
65% B, 15.0–17.0 min 75% B, 17.0–18.5 min 85% B, 18.5–19.5 min 95% B, 19.5–21 min 10%
B, 21.0–25.0 min 10% B with constant flow rate of 0.3 mL/min. The autosampler temperature
was kept at 10°C and the column at 40°C. The mass analysis was done in negative mode
(AJST-ESI-). For each oxylipin compound, precursor ions [M-H]-, product ions and optimal
collision energies were established for each MRM transition using the MassHunter Optimizer
software. The Source and iFunnel Optimizer was executed for optimizing seven parameters
(capillary, nozzle and nebulizer voltage, gas temperature and flow, and sheath gas temperature
and flow). A compromise had to be made between the optimal conditions for each compound
and the final AJST-ESI- conditions were: capillary and nozzle voltage at 4000 V and 1500 V,
respectively, drying gas temperature 230°C with a gas flow of 15 L/min, sheet gas temperature
400°C with a gas flow of 11 L/min, the nebulizer gas flow was 35 psi, and iFunnel high and low
pressure RF at 90 and 60 V, respectively. The dynamic MRM option was used and performed
for all compounds with optimized transitions and collision energies. Integration of all peaks
was manually performed using the MassHunter Workstation software.
Oxylipin method validation
The method was validated according to the US Food and Drug Administration (FDA) guide-
lines over three consecutive days for linearity, LOD, LOQ, inter- and intraday accuracy and
precision, recovery and stability [50], in line with our previously validated method for endo-
cannabinoid analysis [34]. However, we used the LOD and LOQ definition based on the signal
to noise response, which not automatically translates to the lower limit of quantification
(LLOQ) corresponding to the lowest point in the calibration curve used in the FDA guidelines.
Linearity. At least fourteen different concentrations of each standard were prepared and
analyzed in triplicate. Calibration curves were calculated by the least-squares linear regression
method using the equation y = m(x)+b, where “y” is equal to the response ratios (native stan-
dard peak area/internal standard peak area), “m” is equal to the slope of the calibration curve,
“x” is equal to the on column concentration of the native analyte and “b” is equal to the y-inter-
ception of the calibration curve. Equal weighting factor was used. For concentration determina-
tions of each analyte in real samples, a 10-point calibration curve was used (S4 Table). The
peak area ratio between the analyte and its corresponding internal standard (S2 Table) were
used (“y”) and the concentrations (“x”) were calculated using the calibration curve equation.
Limit of detection (LOD) and Limit of Quantification (LOQ). The limit of detection
(LOD) was defined as the concentration that resulted in a peak with a signal-to-noise ratio (S/
N) greater than three and the limit of quantitation (LOQ) was defined as S/N greater than 10.
Oxylipins and Endocannabinoid Levels in Postprandial Inflammation
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Accuracy and precision. Accuracy and precision were determined using 4 quality control
(QC) samples of 750 μL 100 mM phosphate buffer saline (PBS) spiked with native standard
mixtures at different concentrations (corresponding to on-column values of 96; 24; 12 and
2.9 pg/μL). On three non-consecutive days, three replicates of each QC sample were extracted
by SPE as described above for plasma samples and analyzed by UPLC-AJST-ESI-MS/MS
together with a complete set of calibration standards. Calibration curves obtained for each
batch were used to determine the QC sample concentration.
The intraday accuracy was determined as the percent difference between the expected con-
centration and the mean concentration for each analytical run (n = 3). The interday accuracy
was determined as the percent difference between the expected concentration and the mean
concentration on the three different days (n = 9). The acceptable range of inter- and intraday
accuracy was considered to be 80–120%.
The coefficient of variation (% CV) for the mean concentration was used to calculate the
intra- and interday precision (n = 3 and n = 9, respectively). A CV less than 20% was consid-
ered acceptable.
Recovery. Internal standard recovery rates were established for different matrices in tripli-
cates by adding a recovery standard (CUDA) immediately before UPLC-MS/MS injection to
account for changes in volume and instrument variability. Accordingly, the internal standard
recovery was calculated by spiking, in triplicates, 750 μL of PBS (100 mM) with 10 μL of inter-
nal standard solutions at four different levels (corresponding to on-column values of 9.1, 4.5,
2.3 and 1.1 pg/μL) prior to SPE extraction. Matrix-dependent recovery was established by spik-
ing 10 μL internal standards in a similar manner to human plasma). A 5 point calibration
curve was generated by plotting each internal standard on column concentration vs IS/CUDA
area to calculate the amount of each internal standard recovered through all the extraction
steps, expressed as the percentage of the expected value. This procedure was applied to all the
samples analyzed.
Stability. The stability of each analyte was determined by measuring sample concentra-
tions immediately after collection and at different time points after storage at -20 and -80°C,
and after two freeze-thaw cycles. Stability of analytes in working solutions was determined by
comparing fresh solutions and solutions stored at -80°C for four weeks.
Statistical analysis
Metabolite levels were calculated and expressed as mean ± SEM, using GraphPad Prism 6 (San
Diego, CA, U.S.A.). To detect significant temporal changes in the oxylipin and endocannabi-
noid metabolome during the postprandial response, differences between compound concentra-
tions across the time points were assessed using one-way ANOVA with post hoc Tukey’s
multiple comparison test at α = 0.05 considered significant. Two-tailed and paired Student’s t-
test corrected for multiple comparison with the Holm-Sidak method (α = 0.05) was used to
detect significant differences of each metabolite concentration at each time point between the
vegan and vegetarian background diet. Multivariate data analysis was done using SIMCA soft-
ware (Version 13.0, Umetrics, Umeå, Sweden). All data was mean centered and scaled to unit
variance before modeling.
Results
Endocannabinoid quantification
In the 24 samples analyzed, a total of 12 NAEs, MAGs, and related compounds were detected
with average levels ranging from 0.1 to 211 nM (Table 1). POEA was found at the highest
levels followed by 2-LG, 2-AG, SEA and LEA. All 15 compounds analyzed were present in all
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samples, except for 2-AG and 2-LG (detected in all but one), EPEA (only detected in 3 vegan
samples) and 2-AGe and NADA, which were not detected at all (S5 Table).
Student’s t-test was applied to investigate diet-dependent differences at baseline (during
fasting) and in the postprandial state. There were no significant difference at baseline, and
NAGly was the only compound that showed a significant diet-dependent difference in the
postprandial state (at 0.5 hours after the meal, Fig 2). To our knowledge, this is the first report
of NAGly in human plasma. MRM chromatograms and mass spectra of a plasma sample and a
standard solution to verify its identity are shown in Fig 3.
One-way ANOVA revealed alterations in the postprandial POEA and SEA levels when the
subject was on a vegan diet (Fig 4A), with decreased levels of POEA at 1 and 3 hours after the
meal, and increased levels of SEA at 1 hour after the meal. Only POEA postprandial levels were
altered when the subject was on the modified diet (Fig 4B), with decreased levels at 0.5, 1 and 3
hours after the meal.
Oxylipin quantification
Dynamic MRM with defined retention time windows instead of time segments was performed
allowing the instrument to monitor transitions only during the stated time window and there-
fore reducing the number of concurrent transitions. An extracted MRM chromatogram of all
oxylipins included in the method is shown in Fig 5. No cross-talk between channels that were
used for monitoring quantification standards, internal standards and the recovery standard
was observed.
Separation optimization
Separation of all 37 oxylipins was achieved, including critical pairs of isomers such as PGE2
and PGD2, and Resolvin D1 and D2 with the same MRM transitions (Fig 5). The specific
detection of compounds with overlapping retention times, but different transitions is illus-
trated in S2 Fig. Eluent B acidified with 0.1% acetic acid improved signals for the prostaglan-
dins PGD2, PGE2, PGF2α, and TXB2, but impaired the signals of the other compounds.
Fig 2. Comparison of the postprandial response in NAGly (eCB) plasma levels in one subject on usual
(vegan) andmodified (vegetarian) diet, respectively. *p < 0.05 (adjusted for multiple comparisons).
doi:10.1371/journal.pone.0132042.g002
Oxylipins and Endocannabinoid Levels in Postprandial Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0132042 July 17, 2015 10 / 29
Therefore, eluent B was not acidified in the final protocol. The optimal UPLC conditions, col-
umn temperature, gradient composition and pH were selected based on the resolution and
intensity of each peak. The retention time accuracy for each compound was 99.2%±0.3%
(n = 10).
Fig 3. MRM chromatograms of (A) NAGLy in a standard solution (136 pg on column) and (B) a
representative plasma sample together with corresponding MS spectra (inserts).
doi:10.1371/journal.pone.0132042.g003
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MS/MS optimization. The most intense transition for each analyte was used for quantifi-
cation purposes, marked in bold in the list of MRM transitions, collision energies and cell volt-
ages (Table 2). The second transition was used as a qualifier fragment. Internal standards were
Fig 4. Baseline and postprandial response levels of endocannabinoid significantly different for a subject on usual diet (A), and onmodified diet
(B). Values represent the mean ± SEM (n = 3 for each diet and time point. ****p < 0.0001, ***p = 0.0002, **p = 0.005 (adjusted for multiple comparisons).
doi:10.1371/journal.pone.0132042.g004
Fig 5. MRM chromatograms of each analyte analyzed in a standard solutionmixture (A) and
separation of critical pairs of isomers (B).
doi:10.1371/journal.pone.0132042.g005
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Table 2. Mass spectrometry parameters for multiple reactionmonitoring transitions [Retention Time (RT), Cell Accelerator Voltage (CA), Collision
Energy (CE)], linearity, Limit of Quantification (LOQ), and Limit of Detection (LOD) for the analyzed compounds (Fragmentor Voltage: 380 V for all
compounds).
Compound Abbreviation rt
[min]
Precursor
ion
Transition CA
[V]
CE
[V]
Slope R2 LOD[pg
on
column]
LOQ[pg
on
column]
Linear
range
[pg/μL]
Thromboxane B2-d4 TXB2-d4 7.54 373.25 373.25 < 173.00 7 9 0.0021 0.9993
373.25 < 199.00 7 9
Thromboxane B2 TXB2 7.57 369.23 369.23 < 169.10 7 13 0.051 0.9994 0.01 0.05 0.0053–
215.31
369.23 < 195.00 7 9
9,12,13-trihydroxy-
octadecenoic acid
9,12,13-TriHOME 8.14 329.23 329.23 < 211.10 5 21 0.0549 0.9976 0.0005 0.01 0.0011–
215.31
329.23 < 229.10 5 17
9,10,13-trihydroxy-
octadecenoic acid
9,10,13-TriHOME 8.31 329.23 329.23 < 171.00 7 21 0.0478 0.9954 0.01 0.05 0.0053–
215.31
329.23 < 139.10 7 21
Prostaglandin F2α PGF2α 8.33 353.23 353.23 < 193.30 7 21 0.009 0.9965 0.01 0.05 0.0053–
215.31
353.23 < 211.00 7 21
Prostaglandin E2-d4 PGE2-d4 8.60 355.24 355.24 < 319.20 7 5 0.0031 0.9998
355.24 < 275.20 7 13
Prostaglandin E2 PGE2 8.64 351.21 351.21 < 315.10 7 5 0.0336 0.9985 0.05 0.0053–
215.31
351.21 < 271.20 7 13
Prostaglandin D2 PGD2 9.08 351.21 351.21 < 315.20 6 9 0.033 0.9987 0.26 0.53 0.053–
215.31
351.21 < 271.10 6 13
7S,16R,17S-trihydroxy-
4Z,8E,10Z,12E,14E,19Z-
docosahexaenoic acid
Resolvin D2 9.45 375.21 375.21 < 215.10 4 13 0.0003 0.997 0.53 4.21 0.42–
215.31
375.21 < 216.10 4 13
7S,8R,17S-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-
docosahexaenoic acid
Resolvin D1 9.86 375.21 375.21 < 215.10 4 17 0.0083 0.9988 0.05 0.26 0.026–
215.31
375.21 < 217.1 4 13
Leukotriene B4 LTB4 12.91 335.22 335.22 < 195.10 5 13 0.0141 0.9992 0.05 0.26 0.026–
215.31
335.22 < 317.20 5 13
12,13-dihydroxy-
octadecenoic acid-d4
12(13)-DiHOME-
d4
13.15 317.26 317.26 < 185.10 7 21 0.0008 0.9999
12,13-dihydroxy-
octadecenoic acid
12(13)-DiHOME 13.22 313.24 313.24 < 183.20 7 17 0.048 0.9958 0.01 0.05 0.0053–
215.31
313.24 < 99.00 7 25
9,10-dihydroxy-
octadecenoic acid
9(10)-DiHOME 13.68 313.20 313.20 < 201.00 7 17 0.0852 0.9985 0.0005 0.000053–
215.31
313.20 < 59.10 7 17
14,15-dihydroxy-
eicosatrienoic acid
14,15-DHET 14.03 337.24 337.24 < 207.00 7 13 0.0714 0.9961 0.01 0.05 0.0053–
215.31
337.24 < 129.20 7 17
11,12-dihydroxy-
eicosatrienoic acid
11,12-DHET 14.67 337.24 337.24 < 167.10 7 17 0.0496 0.9974 0.05 0.26 0.026–
215.31
8,9-dihydroxy-
eicosatrienoic acid
8,9-DHET 15.26 337.24 337.24 < 127.20 4 21 0.0152 0.9976 0.05 0.26 0.026–
215.31
(Continued )
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Table 2. (Continued)
Compound Abbreviation rt
[min]
Precursor
ion
Transition CA
[V]
CE
[V]
Slope R2 LOD[pg
on
column]
LOQ[pg
on
column]
Linear
range
[pg/μL]
5,6-dihydroxy-
eicosatrienoic acid
5,6-DHET 15.69 319.23 337.24 < 71.00 7 13 0.007 0.9974 0.05 0.26 0.026–
215.31
337.24 < 145.10 7 13
12-hydroxy-
eicosapentaenoic acid
12-HEPE 16.07 317.21 317.21 < 179.1 7 25 0.0177 0.9978 0.01 0.05 0.0053–
215.31
337.24 < 299.10 7 29
20-hydroxy-
eicosatetraenoic acid
20-HETE 16.09 319.23 319.23 < 289.2 7 9 0.0054 0.9973 0.53 1.05 0.11–
215.31
319.23 < 180.10 7 9
13-hydroxy-
octadecadienoic acid
13-HODE 16.66 295.23 295.23 < 195.10 6 17 0.3034 0.9961 0.05 0.26 0.026–
215.31
295.23 < 277.10 6 17
9-hydroxy-
octadecadienoic acid-d4
9-HODE-d4 16.76 299.25 299.25 < 172.00 6 29 0.0001 0.9996
9-hydroxy-
octadecadienoic acid
9-HODE 16.83 295.23 295.23 < 171.20 6 13 0.3385 0.9986 0.0005 0.000053–
215.31
295.23 < 277.20 6 13
15-hydroxy-
eicosatetraenoic acid
15-HETE 17.05 319.23 319.23 < 219.00 5 9 0.2892 0.9966 0.01 0.05 0.0053–
215.31
319.23 < 301.20 5 5
17(R)-hydroxy-
docosahexaenoic acid
17(R)-HDoHE 17.13 343.23 343.23 < 281.20 7 9 0.0932 0.9944 0.53 1.05 0.11–
215.31
343.23 < 201.30 7 9
13-oxo-octadecadienoic
acid
13-oxo-ODE 17.14 293.21 293.21 < 113.10 7 5 0.0412 0.9981 1.05 4.21 0.42–
215.31
293.21 < 165.20 6 17
15-oxo-eicosatetraenoic
acid
15-oxo-ETE 17.40 317.21 317.21 < 113.20 6 13 0.4556 0.9973 0.05 0.26 0.026–
215.31
317.21 < 273.10 6 9
11-hydroxy-
eicosatetraenoic acid
11-HETE 17.47 319.23 319.23 < 167.20 6 9 0.07352 0.9978 0.01 0.0011–
215.31
12-hydroxy-
eicosatetraenoic acid
12-HETE 17.73 319.23 319.23 < 179.10 6 9 0.327 0.9987 0.05 0.26 0.026–
215.31
8-hydroxy-
eicosatetraenoic acid
8-HETE 17.80 319.23 319.23 < 155.00 6 9 0.2639 0.9993 0.53 1.05 0.11–
215.31
319.23 < 301.20 6 9
15-hydroxy-
eicosatrienoic acid
15(S)-HETrE 17.90 321.24 321.24 < 303.30 6 9 1.2883 0.9988 0.0005 0.01 0.0011–
215.31
321.24 < 221.10 6 13
12-oxo-eicosatetraenoic
acid
12-oxo-ETE 17.95 317.21 317.21 < 273.30 4 9 0.6082 0.9958 0.01 0.05 0.0053–
215.31
317.21 < 153.20 4 13
9-hydroxy-
eicosatetraenoic acid
9-HETE 18.01 319.23 319.23 < 167.20 4 9 0.076 0.9996 2.1 4.21 0.42–
215.31
319.23 < 123.10 4 17
5-hydroxy-
eicosatetraenoic acid
5-HETE 18.28 319.23 319.23 < 115.10 4 13 0.2269 0.997 0.05 0.26 0.026–
215.31
319.23 < 301.10 4 5
(Continued )
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assigned to each native standard according to their structural similarities and hence retention
time (S2 Table), with the exception of 14(15)-EET, 11(12)-EET, 5-oxo-ETE, 8(9)-EET, and 5
(6)-EET that were eluting close to 12(13)-EpOME-d4 but were assigned to 9(S)-HODE-d4,
because of superior linearity of the latter.
Strassburg et al. [47] developed a method to analyze 104 oxylipins in a single analytical run
using similar equipment to ours (without the iFunnel technology). Their 104-oxylipin method
includes oxylipins that are also included in our method, with the exception of Resolvin D1 and
D2. They used the same transitions as the ones reported here, except for PGE2, 5,6-DHET,
12-HEPE, 13-HODE, 9-HODE, 15-HETE, 5-HETE, and 12(13)-EpOME.
Linearity, LOD and LOQ. The linearity of the method was determined with calibration
curves over a concentration range of 0.05–2200 pg on column. Regression analysis without
weighing factors produced R2 values between 0.9938 and 0.9996 (Table 2). The LOD ranged
between 0.0005 and 2.1 pg on column, while LOQ ranged between 0.0005 and 4.2 pg on col-
umn (Table 2). Yang et al. [46] established LOQ values between 0.03 and 15.96 pg on column.
Their LOQs for 15-oxo-ETE, 9-HETE, 11,12-DHET, and LTB4 were lower compared to ours.
For all other compounds their LOQ values were equal or higher than ours. A comparison of all
individual LOQs can be found in S6 Table.
Wang et al. [48] recently reported a comprehensive method for analysis of eicosanoids and
other bioactive lipids in human plasma (184 compounds). However, the 35 compounds in
common with our method presented higher LOQ values (S6 Table). Furthermore, a combined
method to quantify prostanoids and N-acylethanolamines in human plasma included a sub-set
of the compounds in our method, but also with higher LOQ values [49].
Despite the advantage illustrated above of a large panel of compounds analyzed with a short
run time [26, 48, 49], a compromised sensitivity is unavoidable with current MS equipments.
Table 2. (Continued)
Compound Abbreviation rt
[min]
Precursor
ion
Transition CA
[V]
CE
[V]
Slope R2 LOD[pg
on
column]
LOQ[pg
on
column]
Linear
range
[pg/μL]
12(13)epoxy-
octadecenoic acid-d4
12(13)-EpOME-
d4
18.44 299.25 299.25 < 281.00 4 4 0.0002 0.9997
12(13)epoxy-
octadecenoic acid
12(13)-EpOME 18.52 295.23 295.23 < 195.10 5 13 0.127 0.9938 0.26 0.53 0.053–
215.31
295.23 < 277.20 5 13
14(15)-epoxy-
eicosatrienoic acid
14(15)-EET 18.54 319.22 319.22 < 219.00 5 5 0.2564 0.9983 0.01 0.05 0.0053–
215.31
319.22 < 301.00 5 5
9(10)epoxy-
octadecenoic acid
9(10)-EpOME 18.72 295.23 295.23 < 171.20 4 13 0.1252 0.9969 0.26 0.53 0.053–
215.31
5-oxo-eicosatetraenoic
acid
5-oxo-ETE 19.00 317.23 317.23 < 203.20 4 13 0.1555 0.9968 0.05 0.26 0.026–
215.31
317.23 < 59.10 4 21
11(12)-epoxy-
eicosatrienoic acid
11(12)-EET 18.96 319.23 319.23 < 167.10 4 9 0.4723 0.9986 0.01 0.05 0.0053–
215.31
319.23 < 301.2 4 5
8(9)-epoxy-
eicosatrienoic acid
8(9)-EET 19.17 319.23 319.23 < 69.20 4 13 0.0773 0.9995 ND 0.26 0.026–
215.31
319.23 < 123.00 4 5
5(6)-epoxy-
eicosatrienoic acid
5(6)-EET 19.34 319.23 319.23 < 191.10 4 5 0.1049 0.9996 0.26 0.53 0.053–
215.31
doi:10.1371/journal.pone.0132042.t002
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Therefore, we decided to select a sub-set of compounds including those previously reported in
human plasma and others of potential interest to postprandial inflammation.
Accuracy and precision. Four QC samples at different concentrations were used to estab-
lish accuracy and precision of the method (S7 Table). In the current study, the sample on-col-
umn amounts were in general close to QC3 and QC4, and occasionally at the level of QC2.
Precision ranged from 0.1 to 17%, and were in general 5% or below (for 3/4 of the samples).
Only 1/20 of the QC samples displayed CV values of 10% or higher. Hence, conditions for a
precise method were achieved for all oxylipins tested according to the FDA guidelines of CV
below 20%. Furthermore, the majority of QC samples (4/5) were in the range of 85 to 115%,
thereby fulfilling the FDA guidelines of accuracy (80–120%). However, the accuracy ranged
from 48 to 175% at the lowest QC level for 5 compounds (9,10,13-TriHOME, PGF2α, 12(13)-
EPOME, 5(6)-EET and 12-oxo-ETE).
Recovery. The average recovery rates ranged from acceptable 71 to 109% in PBS, human,
fish and pig plasma, as well as CSF (Fig 6), except for the recovery of 12(13)-EpOME-d4 in
plasma, which was approximately 40%. The recovery for internal standards was considered
representative of the recovery for the native compounds, thus good recovery rates for internal
standards ensure well-functioning extraction and analysis of the endogenous oxylipins. It has
previously been shown that the polarity of each compound influences the recovery from differ-
ent matrices according to their lipophilicity and/or presence of protein [51]. Our results con-
firm PBS to mimic human plasma with similar recovery rates for the internal standards.
Stability. Stability tests of human plasma analyzed after 7, 31 and 300 days in -80°C
showed that the oxylipins were stable over the whole period (up to 300 days) with the exception
of 15-oxo-ETE (S8 Table). Two cycles of freeze-thaw (at -20°C for one week) resulted in a
higher degree of degradation when compared to the longest storage time at -80°C. The stability
values in human plasma for the endocannabinoids and related compounds were in line with
those reported in bovine milk [34].
Analysis of changes in metabolites. In the 24 human plasma samples analyzed, 35 oxyli-
pins derived from 4 different PUFAs and biosynthesized via three different pathways (COX,
LOX, and CYP) could be detected (Table 3). These results are in accordance to other studies,
which also quantified a variety of oxylipins in human plasma [27, 47]. Twenty-six oxylipins
Fig 6. Average recovery rates for deuterated internal standards (IS) in PBS (n = 5) and human plasma
(n = 24) Expressed as mean±SEM.
doi:10.1371/journal.pone.0132042.g006
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Table 3. Average levels (nM)±SEM of compounds in the oxylipin metabolome of human plasma at fasting (baseline) and in the fasting and post-
prandial state (all samples) in a subject on her usual or modified diet.
Usual Diet Modified Diet
Oxylipin Fatty acid
precursor
Chemical
class
Pathway Baseline
(n = 3)
All samples
(n = 12)
Range Baseline
(n = 3)
All samples
(n = 12)
Range
TXB2 AA Triol COX 1.16±0.052 0.91±0.1 0.26–1.3 0.39±0.073 0.86±0.14 0.22–
1.69
9,12,13-TriHOME LA Triol 5-LOX 0.72±0.028 0.82±0.064 0.51–1.3 1.92±1.2 1.34±0.34 0.47–
4.41
9,10,13-TriHOME LA Triol 5-LOX 0.96±0.008 1.08±0.078 0.75–1.6 2.65±1.7 1.96±0.45 0.72–
6.03
PGF2α AA Triol COX 0.30±0.045 0.36±0.023 0.22–
0.52
0.44±0.015 0.38±0.018 0.30–
0.47
PGE2 AA Diol/Ketone COX 0.25±0.030 0.21±0.012 0.15–
0.30
0.18±0.016 0.21±0.01 0.14–
0.26
PGD2 AA Diol/Ketone COX 0.05±0.012 0.04±0.005 0.02–
0.08
0.05±0.005 0.05±0.003 0.04–
0.07
12(13)-DiHOME LA Diol CYP 9.61±1.2 6.77±0.70 3.35–
11.9
5.30±1.7 3.70±0.61 1.22–
8.68
9(10)-DiHOME LA Diol CYP 6.02±0.41 4.26±0.43 2.05–
6.78
3.59±1.4 2.41±0.48 0.62–
6.29
14,15-DHET AA Diol CYP 0.57±0.11 0.42±0.038 0.29–
0.78
0.30±00.055 0.28±0.021 0.18–
0.37
11,12-DHET AA Diol CYP 0.31±0.071 0.21±0.024 0.14–
0.45
0.13±0.010 0.12±0.008 0.07–
0.19
8,9-DHET AA Diol CYP 0.13±0.030 0.10±0.009 0.07–
0.19
0.09±0.008 0.08±0.006 0.04–
0.11
5,6-DHET AA Diol CYP ND 0.01±0.008 ND ND 0.01±0.012 0.00–
0.14
12(S)-HEPE EPA Alcohol 15-LOX 0.06±0.05 0.05±0.006 0.02–
0.10
0.07±0.033 0.09±0.017 0.03–
0.23
20-HETE AA Alcohol CYP 0.23±0.077 0.16±0.024 0.05–
0.37
0.06±0.057 0.06±0.021 0.00–
0.22
13-HODE LA Alcohol 5-LOX 17.35±1.2 12.13±1.5 4.34–
19.67
30.8±22 11.85±5.8 3.46–
75.81
9-HODE LA Alcohol 5-LOX 12.64±1.1 7.82±1.07 2.92–
13.95
19.8±15 7.24±4.0 1.92–
51.08
15-HETE AA Alcohol 15-LOX 0.73±0.13 0.52±0.063 0.19–
0.97
0.87±0.57 0.52±0.14 0.25–
2.02
17-HDoHE DHA Alcohol 15-LOX ND 0.03±0.035 0.00–
0.42
1.11±1.1 0.28±0.28 0.00–
3.32
13-oxo-ODE LA Ketone 5-LOX 6.12±0.67 3.73±0.60 1.18–
7.26
10.69±9.4 3.39±2.4 0.27–
29.46
11-HETE AA Alcohol 15-LOX 0.25±0.034 0.17±0.023 0.06–
0.32
0.23±0.13 0.16±0.032 0.08–
0.49
15-oxo-ETE AA Ketone 15-LOX 0.17±0.027 0.12±0.014 0.05–
0.21
0.38±0.32 0.16±0.079 0.04–
1.02
12-HETE AA Alcohol 15-LOX 0.79±0.12 0.58±0.10 0.16–
1.30
0.41±0.17 0.71±0.17 0.18–
2.02
8-HETE AA Alcohol 15-LOX 0.20±0.042 0.12±0.018 0.07–
0.28
0.17±0.10 0.10±0.026 0.04–
0.36
15(S)-HETrE AA Alcohol 15-LOX 0.13±0.031 0.11±0.015 0.06–
0.23
0.20±0.16 0.11±0.038 0.03–
0.52
12-oxo-ETE AA Ketone 15-LOX 0.82±0.053 0.73±0.046 0.44–
0.93
0.75±0.13 0.69±0.033 0.55–
0.99
(Continued)
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were detected in all samples and at all-time points independent of background diet (both usual
and modified diets), 20-HETE was detected in all samples on usual diet and 7/12 of modified
diet samples, 8(9)-EET, 11(12)-EET, and 5-oxo-ETE were detected in all except one or two
samples, while 5 oxylipins (LTB4, 5,6-DHET, 17(R)-HDoHE, 9-HETE and 14(15)-EET were
detected irregularly (S9 Table). Two compounds, Resolvin D1 and 2, were not detected at all.
Measurable concentrations of Resolvin D1 and 2 were, however, previously found in human
plasma following ω3 fatty acid supplementation [52]. Resolvins are known to act as lipid medi-
ators in the resolution of inflammation [53] and might therefore not be present, or only at very
low concentrations, in plasma of a healthy subject.
Oxylipins above LOQ and with S/N> 10 were included in the statistical calculations of the
postprandial response. For oxylipins with S/N> 10 (but levels below LOQ), the concentration
was calculated using an extrapolated calibration curve. For oxylipins with S/N between 3 and
10 (and levels below LOQ), the value of LOD was used. In total, the variability of 35 oxylipins
was investigated.
Oxylipin levels ranged over three orders of magnitude from 0.01 to 76 nM, where baseline
levels on usual diet ranged from 0.03 to 19 nM and modified diet baseline levels ranged from
0.03 to 76 nM (Table 3).
Of all oxylipins tested, only one compound (TXB2) displayed significantly different baseline
levels between the different background diets. There were decreased TXB2 levels when the sub-
ject was on the modified diet compared to the usual background diet (Fig 7). TXB2 is an inac-
tive COX product of arachidonic acid (AA, 20:4n6). Its precursor, TXA2, is the major COX
product in blood platelets and acts as a pro-aggregator and vasoconstrictor [54]. According to
Sinclair et al [55], diets rich in AA show no effect on levels of TXA2, suggesting that differences
in TXB2 levels are not caused by dietary AA changes. In contrast, a connection between AA
Table 3. (Continued)
Usual Diet Modified Diet
Oxylipin Fatty acid
precursor
Chemical
class
Pathway Baseline
(n = 3)
All samples
(n = 12)
Range Baseline
(n = 3)
All samples
(n = 12)
Range
9-HETE AA Alcohol 15-LOX 0.07±0.005 0.03±0.012 0.00–
0.10
0.07±0.072 0.06±0.018 0.00–
0.22
5-HETE AA Alcohol 5-LOX 0.30±0.069 0.19±0.028 0.08–
0.43
0.46±0.33 0.20±0.085 0.06–
1.13
12(13)-EpOME LA Epoxide CYP 1.74±0.19 1.28±0.17 0.61–
2.31
1.80±1.1 0.75±0.30 0.10–
3.92
14(15)-EET AA Epoxide CYP 0.05±0.017 0.03±0.007 0.00–
0.08
0.07±0.046 0.03±0.013 0.00–
0.16
9(10)-EpOME LA Epoxide CYP 3.67±0.49 2.54±0.28 1.04–
4.62
4.30±2.9 1.74±0.77 0.46–
10.19
11(12)-EET AA Epoxide CYP 0.13±0.027 0.09±0.013 0.00–
0.18
0.15±0.035 0.11±0.012 0.06–
0.20
5-oxo-ETE AA Ketone 5-LOX 0.06±0.010 0.06±0.012 0.00–
0.16
0.19±0.24 0.09±0.040 0.00–
0.52
8(9)-EET AA Epoxide CYP 0.11±0.032 0.07±0.012 0.02–
0.17
0.13±0.095 0.07±0.024 0.00–
0.32
5(6)-EET AA Epoxide CYP 0.25±0.056 0.14±0.024 0.06–
0.30
0.28±0.14 0.13±0.040 0.02–
0.55
AA – Arachidonic acid (20:4n6)); LA – Linoleic acid (18:2n6); DHA – Docosahexaenoic acid (22:4n6); EPA – Eicosapentaenoic acid (20:5n3); ND – Not
detected.
doi:10.1371/journal.pone.0132042.t003
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concentration in plasma and TXB2 production in phenylketonuric subjects and lower concen-
trations of TXB2 in serum was found [56].
Beside the TXB2 decrease in baseline oxylipin levels due to a modified background diet, an
additional six oxylipins showed significantly lower levels at one or more time points during the
postprandial state when the subject was on the modified diet compared to the usual back-
ground diet (Fig 8). Notably, TXB2 showed no significant differences between background
diets in the postprandial state, only at baseline. During the postprandial response, two linoleic
acid (LA, 18:2n6) products from the LOX pathway (9-HODE and 13-oxo-ODE), showed sig-
nificant differences at one hour after the meal between the usual and modified background
diets. Furthermore, significantly different levels were detected in four CYP- derived oxylipins;
both from the LA precursor (9(10)-EpOME and 12(13)-EpOME), and the AA precursor
(20-HETE and 11,12-DHET).
One-way ANOVA revealed significant differences across the time points in the postprandial
oxylipin response (Fig 9). Alterations in the postprandial oxylipin levels were observed only
for compounds derived from LA. For the diols, biosynthesized via the CYP pathway, a signifi-
cant decrease was visible in vegan samples at 1 hour (9(10)-DiHOME) and at 0.5, 1, and 3
hours (12(13)-DiHOME) after the meal compared to the baseline level (at fasting). Further-
more, the ketone 13-oxo-ODE from the LOX pathway also displayed a significant decrease at
0.5 and 1 hour after the meal compared to the baseline level in usual diet samples. Other LOX
products, 9-HODE and 13-HODE (alcohols), were found to also decrease in comparison to
baseline for both usual and modified diet samples at 0.5, 1, and 3 hours after the meal. No sig-
nificant changes, however, were observed for COX-derived metabolites (e.g. prostaglandins).
Profiling of the oxylipin and endocannabinoid metabolome
Coefficient of variation (CV) values for the oxylipins, NAEs, MAGs and related compounds in
human plasma (S3 and S4 Figs were considerably larger than those found for quality control
samples of standards spiked to PBS (S10 and S11 Tables). Hence, the variability of the plasma
metabolites was attributed to biological variation rather than analytical. For the purpose of
investigating if the biological variation was due to noise, or if there was a true signal from the
background diet, multivariate data analysis was performed combining the information from all
Fig 7. Significant different baseline levels of TXB2 (p = 0.001) in plasma collected at usual (n = 3) and
modified (n = 3) background diets, respectively. Values represent the mean ± SEM.
doi:10.1371/journal.pone.0132042.g007
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Fig 8. Comparison of the postprandial oxylipin plasma levels in one subject on a usual andmodified diet, respectively. * indicates p < 0.05 (adjusted
for multiple comparisons).
doi:10.1371/journal.pone.0132042.g008
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oxylipins found in all samples (n = 26), and NAEs, MAGs and related compounds found in all
but one or two samples (n = 11). We chose a conservative approach and included only the
metabolites in common between all samples (but one or two) to ensure that the same metabolic
domain was captured for all samples. The relationship between systematic variability and back-
ground diet (usual and modified) was investigated using multivariate regression analysis in
Fig 9. Baseline and postprandial response levels significantly different of oxylipins for a subject on
usualdiet (A), and onmodified diet (B). Values represent the mean ± SEM (n = 3 for each diet and time
point). Brackets indicates significantly different time points: ****p < 0.0001, ***p = 0.0002 (adjusted for
multiple comparisons).
doi:10.1371/journal.pone.0132042.g009
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terms of orthogonal projections to latent structures discriminant analysis (OPLS-DA) [57].
When data from only baseline samples were included (n = 6), the result was no significant
OPLS-DA model assessed by ANOVA based on the cross-validated score vectors (CV-A-
NOVA: 0.764) [58]. The reason might be the low number of samples, however, adding all sam-
ples to the model (n = 24), resulted also in no significant model (CV-ANOVA: 0.267). On the
contrary, only using data from the samples in the postprandial state (n = 18) resulted in a sig-
nificant separation between samples collected during the usual and modified background diets
(Fig 10). This was in agreement with the univariate data analysis, with only one metabolite
showing a significant difference at baseline (TXB2), while 7 (NAGLy, 9-HODE, 13-oxo-ODE, 9
(10)-EpOME, 12(13)-EpOME, 20-HETE, and 11,12-DHET) were different between the back-
ground diets in the postprandial state. However, the majority of the metabolites showed no dif-
ference due to background diet in univariate analysis, and among the ones responsive to the
challenge meal, several metabolites were in common between the background diets (POEA,
9-HODE, and 13-HODE), highlighting the additional value of using multivariate data analysis in
nutritional studies, which also previously has been recommended and frequently applied [59].
Furthermore, from the multivariate analysis we could conclude that metabolites in the oxylipin
metabolome were more specific to each background diet than metabolites in the endocannabi-
noid metabolome, since only oxylipins displayed variable importance above 1, the limit for vari-
able influence on projection considered to be relevant for separation of classes (S12 Table). LA
derived epoxides in the CYP pathway (9(10)-EpOME and 12(13)-EpOME) were characteristic of
the usual diet, and could be due to the higher levels of LA in the diet during this time period. On
the other hand, an eicosapentaenoic acid derived oxylipin in the LOX pathway (12(S)-HEPE)
dominated when the subject was on the modifieddiet in relation to the whole oxylipin and eCB
metabolome under study (S5 Fig). This was despite the fact that intake of eicosapentaenoic acid,
or its precursor, alpha-linolenic acid, were not different between the two diets.
To summarize, our results from the multivariate analysis imply that 1) combined data on
the metabolite levels is more informative than each metabolite one by one, and 2) data on the
oxylipin and endocannabinoid metabolome from the postprandial state contain more informa-
tion than from the fasting state alone.
Discussion
This study did not attempt to relate changes in diet (vegan to vegetarian) to biological markers.
The change in background diet rather represented a venue to investigate the performance of
Fig 10. Oxylipin and endocannabinoid profiles in the postprandial state recapitulated as orthogonal
scores (t[1] and to[1]) calculated by OPLS-DA. Time after challenge meal (in hours) is found next to each
sample. The subject displayed different oxylipin and endocannabinoid metabolomes on usual (grey circles)
vs modified (black squares) background diet. Model assessment parameters were: 1 predictive and 1
orthogonal component, p-value calculated by CV-ANOVA: 0.033, total systematic variation among the
metabolites captured by the model (R2X): 0.463, total systematic variation between the diets captured by the
model (R2Y): 0.815, predictive ability of the model (Q2): 0.53.
doi:10.1371/journal.pone.0132042.g010
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the UPLC-ESI-MS/MS methods to detect subtle fluctuations among the bioactive lipids, in this
case introduced by the difference in diets, within a single subject tested with the challenge meal
study design at multiple occasions. Thereby, the investigation served as a pilot study in which
the biological variability was assessed and compared to the analytical variability of the
UPLC-ESI-MS/MS methods. From our multivariate analysis it was evident that inclusion of
dairy products in the diet produced a shift in bioactive lipid profiles in the postprandial state
(Fig 10), most notably among the oxylipins (S5 Fig and S8 Table). This shift was not present
to the same extent in the fasting state alone suggesting that a subtle change in metabolite levels
occurred in the postprandial state (which was successfully detected with our analytical proto-
cols). Indeed, there was one analyte in the endocannabinoid metabolome (NAGly) and 6 in the
oxylipin metabolome (20-HETE, 9,(10)-EpOME, 11,12-DHET, 9-HODE, 13-oxo-ODE and 12
(13)-EpOME) that were significantly different in the postprandial state, while only one (TXB2)
was different in the fasting state, and not in the postprandial state (Fig 2 and Fig 8). So, the
shift seemed to be analyte-dependent, some diverged in the postprandial state, while others
converged between vegan and vegetarian diets. At the same time, there were similarities in
metabolite responsiveness between the usual and modified diets. Two NAEs (POEA and SEA)
and 5 oxylipins (9(10)-DiHOME, 12(13)-DiHOME, 9-HODE, 13-HODE and 13-oxo-ODE)
were responsive to the challenge meal when the subject was on the usual diet, of which 1 NAE
(POEA) and 2 oxylipins (9-HODE and 13-HODE) also were responsive when the subject was
on a vegetarian diet (Fig 4 and Fig 9). Whether the discrepancy in responsiveness is due to
more variable data produced by the modified diet remains to be tested. Our data suggest that
this might be the case, since higher CVs, especially at fasting, were displayed for the samples
collected at modified diet compared to the usual diet (S3 and S4 Figs). But since only one sub-
ject was included in this pilot study, no statement can be made on inter-individual variations
in order to assess the observed variations between the vegan and vegetarian diet.
Furthermore, the study design does not clarify if the variability was caused by true metabolic
differences between the usual and modified diet, or if daily variations in diet and lifestyle that
are independent of specific vegan and vegetarian aspects had an impact. We deliberately
refrained from instructions that would limit lifestyle etc, in order to investigate how well our
UPLC-ESI-MS/MS methods perform for assessment of the oxylipin and endocannabinoid
metabolome in a free-living individual. However, to gain better understanding of dietary effects
on bioactive lipid profiles, it is necessary to carry out further comprehensive studies, including
additional endpoints, on more subjects. For instance, it would be valuable to follow the post-
prandial state over a prolonged time course (more than 3 hours) and also follow for instance
the insulin levels. We selected 3 hours since it represents the lipemic peak [60]. The experiment
was stopped at 3 hours since the challenge meal only provided 15% of daily calories. But with
another type of challenge meal, it would be possible to prolong the experiment.
In addition to the 3 hour time point, we also measured the bioactive lipid levels in the early
postprandial state, since we hypothesized that the metabolites under study would be fast
responders to the meal intake. This proved to be true, since all of the postprandial responses
were detected within 1 hour after the meal intake, and all except 3 out of 10 persisted until 3
hours after the meal intake (Fig 4 and Fig 9). Interestingly, all metabolites (except SEA)
responded by decreasing levels, which might be a reflection of the low content of precursor
fatty acids in the challenge meal (banana). Whether this is characteristic of postprandial
inflammation or attributed to a normal homeostatic response remains to be tested. Our data
confirms that the oxylipin and endocannabinoid metabolome are responsive to a challenge
meal and that small fluctuations in their concentrations can be detected and quantified repro-
ducibly. In addition, we found that multivariate analysis highlighted the subtle diet-dependent
changes in the postprandial state. Therefore, UPLC-ESI-MS/MS analysis of these metabolites
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using a well-validated method can be used to investigate subtle changes expected in lipid-medi-
ated inflammation in connection to meal intake and other clinical conditions and settings
where subtle variations are important to detect.
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